DB
TNXP icon

Dmitry Balyasny’s Tonix Pharmaceuticals TNXP Stock Holding History

Dmitry Balyasny’s Portfolio TNXP Stock Details TNXP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.69M Sell
132,591
-180,491
-58% -$2.33M ﹤0.01% 1908
2026
Q1 		$4.3M Buy
313,082
+127,730
+69% +$1.97M 0.01% 1427
2025
Q4 		$2.9M Buy
+185,352
New +$3.42M ﹤0.01% 1688
2021
Q2 		– Hold
0
– -$45K – 2352
2021
Q1 		– Hold
0
– – – 1688

Other funds holding TNXP

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JHC
Jones Hill Capital New York $470M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
II
Ishara Investments Los Angeles, California $136M AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Dmitry Balyasny's TNXP Position: Q2 2026 in Review

Dmitry Balyasny reduced its Tonix Pharmaceuticals (TNXP) stake by 58% in Q2 2026, selling an estimated $2.33M and leaving 132,591 shares worth $1.69M. The position accounts for ﹤0.01% of the portfolio, ranked #1908.

Dmitry Balyasny first reported a position in TNXP in Q4 2025 and has held it in 3 quarters since. The position peaked at $4.3M in Q1 2026. 102 funds tracked by Wall St. Rank hold TNXP as of Q2 2026.

  • Dmitry Balyasny held 132,591 shares of Tonix Pharmaceuticals worth $1.69M as of Q2 2026.
  • Dmitry Balyasny sold 180,491 Tonix Pharmaceuticals shares in Q2 2026, an estimated $2.33M.
  • Tonix Pharmaceuticals made up ﹤0.01% of Dmitry Balyasny's portfolio in Q2 2026, its #1908 holding.
  • Dmitry Balyasny first reported a position in Tonix Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
  • Dmitry Balyasny's Tonix Pharmaceuticals position peaked at $4.3M in Q1 2026.
  • 102 funds tracked by Wall St. Rank held Tonix Pharmaceuticals as of Q2 2026.

Based on Balyasny Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.